Skip to content

Tranexamic Acid in Hip Fracture Surgery

Effectiveness of Tranexamic Acid (TXA) in Reducing Blood Loss in Hip Fracture Surgery

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02736383
Enrollment
142
Registered
2016-04-13
Start date
2016-05-31
Completion date
2017-07-31
Last updated
2023-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Fracture

Brief summary

To determine if TXA utilization is effective at reducing transfusion rates in elderly patients undergoing surgery for treatment of a hip fractures.

Interventions

None listed

Sponsors

Corewell Health West
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Acute, isolated, unilateral femoral neck, intertrochanteric, and per trochanteric hip fractures confirmed by anteroposterior/lateral hip radiographs, computed tomography, or magnetic resonance imaging. * Age 65 and older * Low energy mechanism of injury * Hip fracture fixation performed within 48 hours * English speaking * Anticipated medical optimization for operative fixation * No other major trauma

Exclusion criteria

* Retained hardware around the affected hip * Infection around the affected hip * Transfer patients with a length of stay \> 24 hours at the transferring hospital * Diagnosis of deficient natural anticoagulation * Known congenital thrombophilia (Deficiency of Protein C, S, Antithrombin) * Known allergy to TXA * Patients undergoing percutaneous pinning of the hip fracture

Design outcomes

Primary

MeasureTime frameDescription
Blood Transfusion Rate6 weeksBlood transfusion rates during the patients hospital stay will be assessed.

Secondary

MeasureTime frameDescription
Hospital Length of stay6 weeksThe patients length of stay in the hospital will be determined.
Post operative complications6 weeksPost operative complications will be assessed through the 6 weeks.
Hospitalization costs6 weeksEconomic evaluation for inpatient and re-admission will be assessed.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026